- Results from the UAE’s first CAR T-Cell experiment have been highly positive, marking the first step towards proving the safety and effectiveness of this new cancer treatment
ABU DHABI:- Abu Dhabi Stem Cells Center (ADSCC), a leading research institute in Abu Dhabi, has successfully completed the first experiment of its kind in the UAE to locally manufacture CAR T-Cells in a laboratory. The UAE is now one step closer to beginning clinical trials to prove the safety and effectiveness of CAR T-Cell therapy in treating hematologic cancers.
Speaking to the significance of these results, Dr Yendry Ventura Carmenate, Specialist in Immunology, General Manager of ADSCC and Principal Investigator of the CAR T-Cell clinical trial, said: “In the twelve days since we began our experiment, we are happy to report that we have successfully manufactured and expanded autologous CAR T-cells from a healthy volunteer in partnership with Miltenyi Biotec. Most significantly, we have been able to achieve the cells’ expansion with the highest levels of quality control and productivity, attaining a higher-than-average cell count with no contamination. This is a highly encouraging result as it demonstrates that it is possible to efficiently manufacture CAR T-cells that exceed acceptable standards of purity, viability and cell dosage for clinical application.”
In this first experiment, researchers at ADSCC combined their in-house expertise with cutting-edge technology to closely monitor, synthesize, and facilitate the rapid yield of functional CAR T-Cells. At this initial stage, the primary objective was to validate the technology and ensure standardization as the homegrown research institute prepares to enter the next stage of clinical trials.
Dr Fatema Al Kaabi, Director of the Abu Dhabi Bone Marrow Transplant Program and Co-Principal Investigator of the CAR T-Cell clinical trial, said: “This amazing result was achieved through the effective combination of our leading team of stem cell researchers and technicians at ADSCC and the highly specialized technology and know-how provided by our partners at Miltenyi Biotec. We are entering an exciting phase in our journey to build the UAE’s first CAR T-Cell treatment program and give hope to patients suffering from various hematologic cancers. We look forward to sharing more progress updates as we prepare to enter clinical trials.”
CAR (Chimeric antigen receptor) T-Cell therapy represents a new, internationally recognized form of immunotherapy that harnesses the body's defense system by reprogramming T-Cells, a crucial component in the body’s anti-tumor response, to go on search-and-destroy missions to kill cancer. These reprogrammed cells become a living drug that mobilizes through the body, continually tapping the immune system to attack disease.
The first of its kind in the UAE, ADSCC was founded in 2019 with the primary objective of meeting growing domestic and regional demand for advanced medical services and the most innovative treatments in the country. ADSCC is focused on delivering cutting edge research on stem cells in the region with the highest standards of quality and patient satisfaction at every step in the process, including treatment and follow-up for personnel, patients, and their families.
-Ends-
For media enquiries, please contact:
Amrit Sharma, H+K Strategies
Amrit.sharma@hkstrategies.com
About Abu Dhabi Stem Cells Center (ADSCC)
The first-of-its kind in the Emirate of Abu Dhabi, Abu Dhabi Stem Cells Center (ADSCC), affiliated with Yas Clinic Group, is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine techniques, as well as delivering cutting-edge research on stem cell therapy in the region.
The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. ADSCC is equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors who work hand-in-hand with researchers.
Specialties include immunology, hematology, clinical stem cell therapy, molecular biology, orthopedics, and urology, amongst others.
The Center primarily focuses on harvesting, processing, characterizing, and storing cell products for clinical application in both regenerative medicine and hematopoietic transplantation. It aims to streamline and develop new processes related to stem cell therapy and research, to both serve the team of doctors’ clinical needs and become a referral center for the region.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
